Skip to content

Study suggests guanabenz may slow Vanishing White Matter disease in kids

By News Analysis India · · 1 min read

Researchers at Amsterdam University Medical Centers examined the impact of guanabenz, a drug normally used to control blood pressure, on children diagnosed with Vanishing White Matter (VWM). Over a three‑year observation period, the treated group showed a delayed need for wheelchair support compared with 66 similar patients who did not receive the medication.

No fatalities occurred among the guanabenz‑treated children, whereas five deaths were reported in the control group. The study noted transient adverse events—visual hallucinations, drowsiness, constipation and occasional hypotension—that largely resolved after the initial months of therapy.